Immunoaffinity Chromatography Segmentation
Product (Columns, Reagents & Kits, Resins)
Based on product, the resins segment is expected to garner a lucrative share of 42.7% in the immunoaffinity chromatography market by the end of 2037. The continuous and escalating demand from biomanufacturers with protein A/G resins is driving the segment’s preeminence over this market. In this regard, the U.S. FDA’s data in 2024 unveiled that above 84% of commercial antibody procedures utilize protein A-based IAC. Further, it is reported that currently bioprocessing facilities are spending USD 1.5 million to 5.4 million annually towards chromatography resins with replacement cycles every 12 to 18 months, facilitating constant revenue in the segment.
Application (Biopharmaceutical Purification, Food & Beverage Testing, Diagnostics & Clinical Research)
In terms of application, the biopharmaceutical purification segment is projected to grow with the highest share of 48.3% in the immunoaffinity chromatography market during the forecast period. The dominance of the segment is subject to a 26% expansion in global biosimilar production in 2023, as of the 2024 WHO report. Testifying to this fact, the EU’s Horizon Europe Program allocated €952 million to advance the development of advanced purification technologies. Moreover, being increasingly adopted towards IAC for long-scale antibody production and vaccine development, regulatory frameworks also offer their extended support for product purity.
Our in-depth analysis of the immunoaffinity chromatography market includes the following segments:
|
Product |
|
|
Application |
|
|
End user |
|
